Beyond Air Inc Revenue Growth Rates (XAIR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Beyond Air Inc   (NASDAQ: XAIR)
 

XAIR's Revenue Growth by Quarter and Year

Beyond Air Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/XAIR/growth
https://api.csimarket.com/api/v1/companies/XAIR/fundamentals
https://api.csimarket.com/api/v1/companies/XAIR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
XAIR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 2.32
1st Quarter June 1.77
FY 4.09

XAIRs Annual Revenue
Beyond Air Inc 's Revenue in the fiscal year 2026 $ 7.68 millions
Beyond Air Inc 's Revenue in the fiscal year 2025 $ 3.34 millions
Beyond Air Inc 's Revenue in the fiscal year 2024 $ 0.69 millions
Beyond Air Inc 's Revenue in the fiscal year 2023 $ 0.66 millions
Beyond Air Inc 's Revenue in the fiscal year 2022 $ 0.00 millions




XAIR Revenue second quarter 2026 Y/Y Growth Comment
Beyond Air Inc reported Revenue improvement of 36.71% year on year in the second quarter 2026, to $ 2.32 millions, this is lower than Beyond Air Inc 's recent average Revenue rise of 51.82%.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 53 other companies have achieved higher Revenue growth. While Beyond Air Inc ' s Revenue rise of 36.71% ranks overall at the positon no. 1000 in the second quarter 2026.


XAIR Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 36.71 %
1st Quarter June 52.59 %
FY   -

Financial Statements
Beyond Air Inc 's second quarter 2026 Revenue $ 2.32 millions XAIR's Income Statement
Beyond Air Inc 's second quarter 2025 Revenue $ 1.70 millions Quarterly XAIR's Income Statement


XAIR Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 31.3 %
1st Quarter June -7.33 %
FY (Year on Year)   -


Back to XAIR Growth rate Comparisons >> Back to XAIR Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #54
Healthcare Sector #196
Overall #1000

Revenue Y/Y Growth Statistics
High Average Low
228.42 % 51.82 % -87.31 %
(Sep 30 2025)   (Sep 30 2020)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #54
Healthcare Sector #196
Overall #1000
Revenue Y/Y Growth Statistics
High Average Low
228.42 % 51.82 % -87.31 %
(Sep 30 2025)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Beyond Air Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
63.6 % -6.92 % -100 %
(Dec 31 2023)  


XAIR's II. Quarter Q/Q Revenue Comment
Beyond Air Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 31.3%, to $ 2.32 millions, from $1.77 millions in the first quarter.

Within Medical Equipment & Supplies industry 160 other companies have achieved higher Revenue quarter on quarter growth. While Beyond Air Inc 's Revenue growth quarter on quarter, overall rank is 3161.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #161
Healthcare Sector #487
Overall #3161
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #161
Healthcare Sector #487
Overall #3161
Revenue Q/Q Growth Statistics
High Average Low
63.6 % -6.92 % -100 %
(Dec 31 2023)  


XAIR's II. Quarter Q/Q Revenue Comment
Beyond Air Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 31.3%, to $ 2.32 millions, from $1.77 millions in the first quarter.

Within Medical Equipment & Supplies industry 160 other companies have achieved higher Revenue quarter on quarter growth. While Beyond Air Inc 's Revenue growth quarter on quarter, overall rank is 3161.


Beyond Air Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 7.30
Y / Y Revenue Growth (TTM) 52.22 %
Year on Year Revenue Growth Overall Ranking # 290
Seqeuential Revenue Change (TTM) 9.32 %
Seq. Revenue Growth (TTM) Overall Ranking # 1000


Cumulative Revenue growth Comment
Assuming the Beyond Air Inc 's fiscal year would have ended in Sep 30 2026, Beyond Air Inc would have reprted above average annual Revenue growth of 52.22% year on year, of $ 7 millions.
This marks a slow-down of the companys growth trends and from the 121.9% surge in Jun 30 2026.

In the Healthcare sector 69 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 290, from total ranking in previous quarter at 3737.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 54
Healthcare Sector # 70
Overall # 290

Revenue TTM Y/Y Growth Statistics
High Average Low
228.42 %
 51.82 %
-87.31 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 196
S&P 500 # 1000
Cumulative Revenue growth Comment
Assuming the Beyond Air Inc 's fiscal year would have ended in Sep 30 2026, Beyond Air Inc would have reprted above average annual Revenue growth of 52.22% year on year, of $ 7 millions.
This marks a slow-down of the companys growth trends and from the 121.9% surge in Jun 30 2026.

In the Healthcare sector 69 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 290, from total ranking in previous quarter at 3737.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 54
Healthcare Sector # 70
Overall # 290

Revenue TTM Y/Y Growth Statistics
High Average Low
228.42 %
51.82 %
-87.31 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 196
S&P 500 # 1000




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XAIR's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions


About Beyond Air Inc Revenue Growth Rates (XAIR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Beyond Air Inc (CIK 1641631).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-051246
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Beyond Air Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.